References
- Calandra S, Dcfesche J, Faergeman O, Hamilton-Craig I, Hegelc R, Hopkins P, et al. Familial Hypercholesterolemia (FH). Report of a WHO Consultation. Geneve: WHO; 1998: 1–68.
- Goldstein JL, Hobbs HH, Brown MS. Familial Hypercholesterolemia. In: Scriver CT, Beaudet Al., Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill; 1995: 1981–2030.
- Tybjaerg-Hansen A, Humphries SE. Familial defective apolipoprotein B-100: a single mutation that causes hypercholesterolemia and premature coronary artery disease. Atherosclerosis, 1992; 96: 91–107.
- Miserez A, Keller U. Differences in the phenotypic characteristics of subjects with familial defective apolipoprotein B-100 and familial hypercholesterolemia. Arterioscler Thromb Vase Biol 1995; 15: 1719–29.
- Hobbs HH, Russell DW, Brown MS, Goldstein JL. The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein. Annu Rev Genet 1990; 24: 133–70.
- Hobbs HH, Brown MS, Goldstein JL. Molecular genetics of the LDL-receptor gene in familial hypercholesterolemia. Hum Mutat 1992; 1: 445–66.
- Winder AF, Day LB. Premature corneal arcus in familial hypercholesterolaemia is characteristic but not a marker of individual coronary risk (abstract). Atherosclerosis 1997; 134: 48.
- Illingworth DR, Duell PB, Connor WE. Disorders of lipid metabolism. In: Felig P, Baxter JD, Frohman A, eds. Endocrinology and Metabolism, 3rd edn. New York: McGraw-Hill; 1995: 1315–405.
- Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group. BMJ 1991: 303: 893–6.
- Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–9.
- Shepard J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1996; 333: 1301–7.
- Connor WE, Connor SL. Importance of diet in the treatment of familial hypercholesterolemia. Am J Cardiol 1993; 72: 42D–53D.
- Tonstad S, Sivertsen M. Food dislikes and dietary intake of children with familial hypercholesterolemia and controls. Scarni J Nutr 1996; 40: 146–50.
- Tonstad S, Leren TP, Sivertsen M, Ose L. Determinants of lipid levels among children with heterozygous familial hypercholesterolemia in Norway. Arterioscler Thromb Vase Biol 1995; 15: 1009–14.
- Tonstad S, Sivertsen M. Dietary adherence in children with familial hypercholesterolemia. Am J Clin Nutr 1997; 65: 1018–26.
- Tonstad S, Aksncs L. Determinants of fat soluble vitamin levels in familial hypercholesterolemia. J Pediatr 1997; 130: 274–80.
- Ose L, Tonstad S. The detection and management of dyslipidaemia in children and adolescents. Acta Paediatr 1995; 84: 1213–5.
- Williams RR, Hamilton-Craig I, Kostner GM, Hcgelc RA, Hayden MR, Pimstone SN, et al. MED-PFD: an integrated genetic strategy for preventing early deaths. In: Berg K, Boulyjenkov V, Christen Y, eds. Genetic Approaches to Non-communicable Diseases. Berlin: Springer-Verlag; 1996: 35–46.
- Ose L, Tonstad S, Vesterhus P, Wefring KW. Detection and management of familial hypercholesterolemia in children and adolescents (in Norwegian). Tidsskr Nor Laegeforen 1995; 115: 3499–503.